GABAA receptor partial agonists and antagonists: structure, binding mode, and pharmacology.

Adv Pharmacol

Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. Electronic address:

Published: July 2015

A high degree of structural heterogeneity of the GABAA receptors (GABAARs) has been revealed and is reflected in multiple receptor subtypes. The subunit composition of GABAAR subtypes is believed to determine their localization relative to the synapses and adapt their functional properties to the local temporal pattern of GABA impact, enabling phasic or tonic inhibition. Specific GABAAR antagonists are essential tools for physiological and pharmacological elucidation of the different type of GABAAR inhibition. However, distinct selectivity among the receptor subtypes (populations) has been shown for only a few orthosteric ligands. Still, these examples show that it is indeed possible to obtain orthosteric subtype selectivity and they serve as models for further development in the orthosteric GABAAR ligand area. This review presents the very few existing structural classes of orthosteric GABAAR antagonists and describes the development of potent antagonists from partial agonists originally derived from the potent GABAAR agonist muscimol. In this process, several heterocyclic aromatic systems have been used in combination with structural models in order to map the orthosteric binding site and to reveal structural details to be used for obtaining potency and subtype selectivity. The challenges connected to functional characterization of orthosteric GABAAR partial agonists and antagonists, especially with regard to GABAAR stoichiometry and alternative binding sites are discussed. GABAAR antagonists have been essential in defining the tonic current but both remaining issues concerning the GABAARs involved and the therapeutic possibilities of modulating tonic inhibition underline the need for GABAAR antagonists with improved selectivity.

Download full-text PDF

Source
http://dx.doi.org/10.1016/bs.apha.2014.10.003DOI Listing

Publication Analysis

Top Keywords

gabaar antagonists
16
partial agonists
12
orthosteric gabaar
12
gabaar
10
agonists antagonists
8
receptor subtypes
8
tonic inhibition
8
antagonists essential
8
subtype selectivity
8
antagonists
7

Similar Publications

GABA Type A receptors expressed in triple negative breast cancer cells mediate chloride ion flux.

Front Pharmacol

October 2024

Department of Pharmaceutical Sciences, Philadelphia College of Pharmacy, Saint Joseph's University, Pharmacology and Toxicology Center, Philadelphia, PA, United States.

Triple negative breast cancer (TNBC) is known for its heterogeneous nature and aggressive onset, limited unresponsiveness to hormone therapies and immunotherapy as well as high likelihood of metastasis and recurrence. Since no targeted standard treatment options are available for TNBC, novel and effective therapeutic targets are urgently needed. Ion channels have emerged as possible novel therapeutic candidates for cancer therapy.

View Article and Find Full Text PDF

Neurosteroids positively modulate GABA receptor (GABAR) channel activity by binding to a transmembrane domain intersubunit site. Using photo-affinity labeling and an ELIC-αGABAR chimera, we investigated the impact of mutations within the intersubunit site on neurosteroid binding. These mutations reduce neither photolabeling within the intersubunit site nor competitive prevention of labeling by allopregnanolone.

View Article and Find Full Text PDF
Article Synopsis
  • - This study focuses on developing new pyrazolo[1,5-a]quinazoline compounds that modify GABA receptors by incorporating oxygen or nitrogen at the 8-position.
  • - The compounds were tested on defined GABA receptor types using an electrophysiological approach, identifying several promising candidates for further research based on their effects on chlorine currents.
  • - Additionally, molecular modeling and statistical analysis (HCA) were used to classify the compounds according to their pharmacological effects, identifying key receptor residues that influence whether a compound acts as an agonist or antagonist.
View Article and Find Full Text PDF

Presynaptic GABA receptors control integration of nicotinic input onto dopaminergic axons in the striatum.

bioRxiv

June 2024

Cellular Neurophysiology Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, 20892, USA.

Axons of dopaminergic neurons express gamma-aminobutyric acid type-A receptors (GABARs) and nicotinic acetylcholine receptors (nAChRs) which are both independently positioned to shape striatal dopamine release. Using electrophysiology and calcium imaging, we investigated how interactions between GABARs and nAChRs influence dopaminergic axon excitability. Direct axonal recordings showed that benzodiazepine application suppresses subthreshold axonal input from cholinergic interneurons (CINs).

View Article and Find Full Text PDF

Identifying new, more efficacious anti-seizure medications (ASMs) is challenging, partly due to limitations in animal-based assays. Zebrafish () can serve as a model of chemical and genetic seizures, but methods for detecting seizure-like activity in zebrafish, though powerful, have been hampered by low sensitivity (locomotor/behavioral assays) or low-throughput (tectal electrophysiology or calcium fluorescence microscopy). To address these issues, we developed a novel approach to assay seizure-like activity using combined locomotor and calcium fluorescence features, measured simultaneously from unrestrained larval zebrafish using a 96-well fluorescent plate reader.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!